Technology for SAVING BRAIN AND LIVES
- This technology is a NOVEL PLATFORM TECHNOLOGY for DRUG DELIVERY SYSTEM for CARDIOVASCULAR DISEASES; NEUROLOGIC DISEASES; CANCER and INFECTIOUS DISEASES.
- Getting Drugs to Their Targets in a Controlled Manner: Many drugs even with the most advanced molecular biology strategies have unacceptable side effects. Due to the drug interacting with healthy tissues that are not the target of the drug.
- UNMET CLINICAL NEED in ACUTE ISCHEMIC STROKE (AIS) and ACUTE PULMONARY EMBOLI – 2 leading, devastating diseases with high mortality and disability. Both are the result of a blood clot (thrombosis) in an artery. Because brain tissue rapidly dies, time to reperfusion is critical in both preventing death and improving neurological outcomes.
- rtPA -THROMBOLITIC THERAPY WITH TISSUE PLASMINOGEN ACTIVATOR is the proven treatment for acute ischemic stroke, pulmonary emboli, heart attack and vascular occlusion. BUT, the success rate is less than 30% and Bleeding and Mortality from TPA are more than 5%.
- WHAT THE COMPAMY DOES: NANOMAGNETIC DRUG DELIVERY
Combine Superparamagnetic Nanoparticles (SPION) made of iron oxide Loaded with tPA (~100 nanometer).
An external Electromagnetic Workstation targets the drug right into the clotted artery.
- VALUE PROPOSITION
- Effective dose reduction (>90%).
- Fast targeting and entry into the clot.
- Controlled release of drug with much improved results.
- Less bleeding and death complication.
- Improved stroke recovery reduced mortality.
- Saving $$$Billions for hospital stay and rehabilitation.
- Market of millions of patients/year.